Molecular Templates Inc Stock News

AUSTIN, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discove

AUSTIN, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery

Molecular Templates Inc (MTEM) shares closed today 23.1% higher than it did at the end of yesterday. The stock is currently down 55.8% year-to-date, down 56.2% over the past 12 months, and up 841.0% over the past five years. Today, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $4.45 and as low as $3.30 this week.Shares closed 72.7% below its 52-week high and 25.8% above its 52-week low.Trading volume this week was 36.1% higher than the 10-day average and 120.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 81.6% The company's stock price performance over the past 12 months lags the peer average by 77.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Molecular Templates Inc (MTEM) shares closed today at 1.5% above its 52 week low of $3.44, giving the company a market cap of $204M. The stock is currently down 61.3% year-to-date, down 63.8% over the past 12 months, and up 689.3% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 27.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 106.3% The company's stock price performance over the past 12 months lags the peer average by 104.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Molecular Templates (NASDAQ:MTEM) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability. Volatility & Risk Molecular Templates has a beta of 1.11, suggesting that its share price is [] The post Analyzing Mirati Therapeutics (NASDAQ:MRTX) & Molecular Templates (NASDAQ:MTEM) appeared first on ETF Daily News .

Barclays reiterated their buy rating on shares of Molecular Templates (NASDAQ:MTEM) in a research report released on Friday morning, Price Targets.com reports. Barclays currently has a $8.00 target price on the biotechnology companys stock. Separately, Zacks Investment Research downgraded shares of Molecular Templates from a buy rating to a hold rating in a research note []

Barclays reiterated their buy rating on shares of Molecular Templates (NASDAQ:MTEM) in a research note issued to investors on Friday, AnalystRatings.com reports. Barclays currently has a $8.00 target price on the biotechnology companys stock. Separately, Zacks Investment Research lowered Molecular Templates from a buy rating to a hold rating in a research note on Friday, []

Molecular Templates, Inc. (NASDAQ:MTEM) Oppenheimer lifted their FY2022 EPS estimates for Molecular Templates in a research report issued on Wednesday, December 1st. Oppenheimer analyst K. Degeeter now anticipates that the biotechnology company will earn ($1.65) per share for the year, up from their previous forecast of ($2.04). Molecular Templates (NASDAQ:MTEM) last posted its earnings []

Credit Suisse AG increased its position in Molecular Templates, Inc. (NASDAQ:MTEM) by 29.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,806 shares of the biotechnology companys stock after buying an additional 4,721 shares during the quarter. Credit Suisse AGs holdings in Molecular Templates []

Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402

Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402

Wall Street analysts expect that Molecular Templates, Inc. (NASDAQ:MTEM) will announce earnings of ($0.30) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Molecular Templates earnings. The lowest EPS estimate is ($0.71) and the highest is $0.08. Molecular Templates posted earnings per share of ($0.53) during the same []

Molecular Templates Inc. (NASDAQ:MTEM)s traded shares stood at 0.37 million during the last session, with the companys beta value hitting 1.06. At the close of trading, the stocks price was $4.35, to imply a decrease of -2.90% or -$0.13 in intraday trading. The MTEM shares 52-week high remains $15.19, putting it -249.2% down since that Molecular Templates Inc. (NASDAQ: MTEM) Has Succeeded In Generating Interest In 2021, The Stock Is Down -53.67% Year-To-Date Read More »

Molecular Templates, Inc. (NASDAQ:MTEM) Investment analysts at Jefferies Financial Group decreased their FY2021 earnings estimates for Molecular Templates in a report issued on Monday, November 15th. Jefferies Financial Group analyst R. Song now expects that the biotechnology company will earn ($1.17) per share for the year, down from their prior estimate of ($0.71). Jefferies []

Molecular Templates, Inc. (NASDAQ:MTEM) Stock analysts at Oppenheimer reduced their FY2021 earnings per share (EPS) estimates for shares of Molecular Templates in a report issued on Monday, November 15th. Oppenheimer analyst K. Degeeter now forecasts that the biotechnology company will post earnings per share of ($1.80) for the year, down from their prior forecast []